Study Status: Recruiting
Recruit Status: Recruiting
Study Type: Interventional
Official Title: Phase I Clinical Trial Using an Engineered Peripheral Blood Graft for Haploidentical Transplantation
Brief Summary:
The goal of this clinical research study is to learn if giving a modified stem cell transplant is less likely to cause graft-versus-host disease (GVHD) to patients with certain types of blood disorders or blood cancers make patients less likely to develop GVHD. Participants will also receive melphalan and fludarabine as part of their regular chemotherapy and total body irradiation (TBI) regimen.
Before participant receives the stem cell transplant, it will be "modified" to remove certain types of T cells that cause GVHD.
GVHD occurs when transplanted immune tissue, such as T cells and stem cells, attacks the tissues of the recipient's body.